LENSAR reported third quarter 2026 revenue of $14.1 million, a 1% year-over-year decrease that missed analyst estimates. Management attributed the decline to lower system sales following a robust prior-year period and typical summer seasonality, though this was largely mitigated by a 17% surge in recurring revenue, which now accounts for 89% of total top-line contribution.

Key Highlights

  • Placed 10 ALLY Robotic Cataract Laser Systems during the quarter, expanding the ALLY installed base to 225 units.
  • Procedure volume grew 12% year-over-year to 52,545, driving procedure-related revenue to $9.2 million.
  • Adjusted EBITDA turned positive at $1.7 million, a significant improvement from the $0.3 million loss recorded in the third quarter of 2025.
  • Maintained a backlog of 12 ALLY Systems pending installation as of September 30, 2026, while ending the period with $12.6 million in cash.